Sarah P. Blagden

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 90 publications

Beyond data and technology: the need for new thinking to enable the era of precision prevention.

Beyond data and technology: the need for new thinking to enable the era of precision prevention.

Journal: BMC medicine

Published: March 09, 2026

Hedgehog Inhibitor and Paclitaxel: A Phase I Trial of the Oral Hedgehog inhibitor Taladegib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours.

Hedgehog Inhibitor and Paclitaxel: A Phase I Trial of the Oral Hedgehog inhibitor Taladegib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours.

Journal: Investigational new drugs

Published: March 03, 2026

Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework.

Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework.

Journal: British journal of cancer

Published: January 16, 2026

Clinical Impact of Next-Generation Sequencing-Guided Targeted Therapies in Advanced Cancer: A Systematic Review and Meta-Analysis.

Clinical Impact of Next-Generation Sequencing-Guided Targeted Therapies in Advanced Cancer: A Systematic Review and Meta-Analysis.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: June 24, 2025

The circulating proteome and cancer risk: a systematic literature review and meta-analysis of 26 prospective studies with genetic validation.

The circulating proteome and cancer risk: a systematic literature review and meta-analysis of 26 prospective studies with genetic validation.

Journal: EBioMedicine

Published: June 16, 2025

Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.

Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.

Journal: The Cochrane database of systematic reviews

Published: March 23, 2025

Precision Prevention Studies: A Targeted Approach to Cancer Prevention.

Precision Prevention Studies: A Targeted Approach to Cancer Prevention.

Journal: Cancer prevention research (Philadelphia, Pa.)

Published: March 04, 2025

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials.

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 14, 2025

A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.

A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.

Journal: British journal of cancer

Published: December 23, 2024

Access divergence to new cancer medicines in the United Kingdom.

Access divergence to new cancer medicines in the United Kingdom.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 16, 2024

A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.

A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.

Journal: Cancers

Published: February 16, 2024

LARP1 haploinsufficiency is associated with an autosomal dominant neurodevelopmental disorder.

LARP1 haploinsufficiency is associated with an autosomal dominant neurodevelopmental disorder.

Journal: HGG advances

Published: January 23, 2024

Showing 1-12 of 90

Last Updated: 09/26/2026